One week treatment with the IL-1 receptor antagonist anakinra leads to a sustained improvement in insulin sensitivity in insulin resistant patients with type 1 diabetes mellitus

In conclusion, one week of treatment with anakinra improves insulin sensitivity in patients with type 1 diabetes.